cmtr1 Antibody

What is CMTR1 and why is it significant in biological research?

CMTR1 (Cap methyltransferase 1) is an S-adenosyl-L-methionine-dependent methyltransferase that mediates mRNA cap1 2'-O-ribose methylation to the 5'-cap structure of mRNAs. This 835 amino acid protein (95.3 kDa) is primarily localized in the nucleus and is widely expressed across many tissue types . CMTR1 plays fundamental roles in RNA metabolism and gene regulation, with significant implications for both normal cellular processes and disease states. It is also known by several synonyms including KIAA0082, MTr1, hMTr1, cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1, FtsJ methyltransferase domain containing 2, and FTSJD2 . Recent multi-omics analyses have revealed CMTR1's widespread upregulation in cancer and its potential as a therapeutic target .

What are the optimal applications for CMTR1 antibodies in research?

• Immunohistochemistry (IHC) for tissue expression analysis, as demonstrated in colorectal cancer studies using tissue microarrays

• Immunoprecipitation for studying protein-protein interactions

• Chromatin immunoprecipitation (ChIP) for investigating CMTR1's association with the transcription start sites of target genes, such as STAT3

• Flow cytometry for analyzing cellular CMTR1 expression levels

The choice of application should be guided by the specific research question, with Western blot serving as the most validated and commonly reported technique in the literature .

How should CMTR1 antibodies be validated before experimental use?

Prior to experimental use, CMTR1 antibodies should undergo rigorous validation through:

• Positive and negative controls: Use cell lines with known high CMTR1 expression (e.g., COLO824 and MDA-MB-468 for breast cancer studies) as positive controls . CMTR1 knockout or knockdown models serve as excellent negative controls.

• Specificity testing: Verify antibody specificity using Western blot to confirm detection of a single band at the expected 95.3 kDa molecular weight .

• Knockdown verification: Test antibody reactivity in CMTR1 knockdown models, as demonstrated in studies using CRISPR-mediated knockout in 4T1 cells and siRNA knockdown in other cancer cell lines .

• Cross-reactivity assessment: When studying CMTR1 in non-human models, verify cross-reactivity with orthologs in species of interest (mouse, rat, bovine, etc.) .

• Lot-to-lot consistency: Confirm consistent performance across different antibody lots using standardized positive controls.

How can CMTR1 antibodies be used to investigate its role in cancer?

CMTR1 antibodies provide critical tools for investigating this protein's role in cancer through multiple approaches:

• Expression profiling: Western blotting and IHC analyses reveal that CMTR1 protein expression is significantly higher in various cancer tissues compared to adjacent normal tissues, with expression levels correlating with pathologic stage and poorer prognosis . For example, IHC staining of colorectal cancer tissue microarrays demonstrated significantly higher nuclear CMTR1 expression compared to adjacent normal tissues .

• Functional studies: Following CMTR1 knockdown or knockout, antibodies can assess the efficacy of depletion and subsequent effects on:

  • Cell proliferation: CMTR1 depletion dramatically inhibits cancer cell growth in vitro

  • Colony formation: CMTR1 knockout reduces clonal growth efficiency in soft agar, a measure of tumorigenicity

  • Signaling pathways: CMTR1 knockdown suppresses STAT3 expression and activation in colorectal cancer

• Mechanistic investigations: CMTR1 antibodies can help elucidate downstream targets through ChIP assays to identify genomic binding sites, revealing that CMTR1 controls cancer cell growth and antitumor immunity by binding to the transcription start site of STAT3 .

What methodological approaches can assess CMTR1's role in immune response?

CMTR1's role in immune response, particularly in interferon signaling and antiviral immunity, can be investigated through:

• Protein expression analysis: Using CMTR1 antibodies to quantify protein levels in response to interferon treatment. Studies show CMTR1 is transcriptionally induced following IFN induction, classifying it as ISG95 (Interferon Stimulated Gene 95) .

• Co-immunoprecipitation: Using CMTR1 antibodies to pull down protein complexes, revealing interactions with immune signaling components.

• Functional knockdown studies: CMTR1 depletion reduces IFN-induced protein levels of ISG15, MX1, and IFITM1 without affecting their transcript abundance, suggesting post-transcriptional regulation . This experimental design requires:

  • Western blot analysis with CMTR1 antibodies to confirm knockdown

  • qRT-PCR to measure transcript levels

  • Western blot to measure protein levels of ISGs

  • Rescue experiments (e.g., IFIT1 knockdown) to restore ISG expression

• Viral replication assays: CMTR1 has been shown to restrict RNA virus replication by ensuring the protein expression of specific antiviral ISGs . These experiments typically include:

  • CMTR1 knockdown or knockout verification by antibody detection

  • Viral infection (e.g., with Zika virus or dengue virus)

  • Quantification of viral replication and correlation with ISG expression levels

How do CMTR1 levels correlate with cancer progression and patient outcomes?

Multi-omics analyses have revealed significant correlations between CMTR1 levels and cancer progression:

Antibody-based detection methods (Western blot, IHC) have been instrumental in establishing these correlations, particularly when combined with survival analysis data from patient cohorts .

What are the optimal conditions for Western blot analysis of CMTR1?

For optimal Western blot analysis of CMTR1:

• Sample preparation:

  • Nuclear extraction is recommended as CMTR1 is primarily nuclear-localized

  • Use protease inhibitors to prevent degradation

  • Include phosphatase inhibitors when studying phosphorylated forms of CMTR1

• Protein loading:

  • Load 20-50 μg of total protein per lane

  • Include positive controls (e.g., COLO824 or MDA-MB-468 cell lysates)

• Running conditions:

  • Use 8-10% SDS-PAGE gels to properly resolve the 95.3 kDa CMTR1 protein

  • Run at 100-120V for optimal separation

• Transfer and detection:

  • Use PVDF membranes and wet transfer (100V for 1-2 hours)

  • Block with 5% non-fat milk or BSA

  • Incubate primary antibody overnight at 4°C at optimized dilution

  • Use appropriate HRP-conjugated secondary antibodies

  • Visualize with enhanced chemiluminescence

• Controls:

  • Include loading controls (β-actin or GAPDH for total lysates, Lamin B1 for nuclear fractions)

  • Use CMTR1 knockout or knockdown samples as negative controls

How can researchers troubleshoot inconsistent results with CMTR1 antibodies?

When encountering inconsistent results with CMTR1 antibodies:

• Specificity issues:

  • Verify antibody specificity using knockout models

  • Test multiple antibodies targeting different epitopes

  • Perform peptide competition assays

• Signal intensity problems:

  • Optimize antibody concentration through titration experiments

  • Adjust exposure time for Western blots

  • Consider enhancing signal with amplification systems

• Background or non-specific binding:

  • Increase washing duration and frequency

  • Optimize blocking conditions

  • Try alternative blocking agents (BSA, casein)

  • Pre-absorb antibody with relevant tissues

• Tissue-specific variations:

  • CMTR1 expression varies across tissue types; adjust protocols accordingly

  • Consider expression differences between cancer subtypes (e.g., higher in basal-like breast cancer)

• Technical considerations:

  • Ensure proper fixation for IHC (paraformaldehyde or formalin)

  • Verify antigen retrieval methods are appropriate

  • Confirm secondary antibody compatibility

How might CMTR1 antibodies facilitate therapeutic target validation?

CMTR1 antibodies can be instrumental in validating this protein as a therapeutic target through:

• Target engagement studies: Using antibodies to verify binding of potential CMTR1 inhibitors (e.g., the novel inhibitor N97911 identified through in silico screening) .

• Biomarker development: CMTR1 antibodies can help establish expression thresholds that predict response to CMTR1-targeted therapies in different cancer types.

• Mechanism verification: Antibodies can confirm that therapeutic effects of CMTR1 inhibition operate through expected mechanisms, such as decreased ribosomal protein gene expression.

• Patient stratification: IHC with validated CMTR1 antibodies could identify patient subgroups most likely to benefit from CMTR1-targeted therapies based on expression levels.

• Combination therapy assessment: CMTR1 antibodies can help evaluate synergistic effects with other treatments, such as the enhanced efficacy of PD1 blockade immunotherapy observed in the presence of CMTR1 knockdown in colorectal cancer models .

What experimental approaches can reveal CMTR1's regulation of target genes?

To investigate CMTR1's regulation of target genes, particularly ribosomal protein genes and 5'TOP motif-containing transcripts:

• ChIP-seq analysis: Using CMTR1 antibodies for chromatin immunoprecipitation followed by sequencing to identify genome-wide binding sites. This has revealed CMTR1's binding to the transcription start site of STAT3 in colorectal cancer .

• RNA immunoprecipitation: To identify direct RNA targets of CMTR1, potentially revealing preference for 5'TOP motif-containing transcripts .

• Transcriptome analysis: RNA-seq following CMTR1 depletion has identified 64 commonly downregulated genes across multiple cell lines, with 53 of these being ribosomal protein genes . This suggests a key role for CMTR1 in regulating ribosome biogenesis.

• Targeted validation: qRT-PCR has confirmed downregulation of multiple ribosomal protein genes (RPS10, RPS14, RPL13A) upon CMTR1 loss in both CMTR1 knockout and siRNA knockdown models .

• Non-coding RNA analysis: CMTR1 also regulates expression of non-coding RNAs, with qRT-PCR showing that snoRNAs SNORD12B and SNORD12C are significantly downregulated in CMTR1-KO cells .

These methodological approaches, facilitated by high-quality CMTR1 antibodies, provide a comprehensive framework for investigating the complex regulatory functions of this increasingly important protein in both normal cellular processes and disease states.